

Rosa Collado

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6322109/publications.pdf>

Version: 2024-02-01

48
papers

1,333
citations

361045

20
h-index

360668

35
g-index

48
all docs

48
docs citations

48
times ranked

2084
citing authors

#	ARTICLE	IF	CITATIONS
1	Cytogenetic risk stratification in chronic myelomonocytic leukemia. <i>Haematologica</i> , 2011, 96, 375-383.	1.7	226
2	Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact. <i>Blood</i> , 2019, 133, 1205-1216.	0.6	164
3	Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma. <i>Genes Chromosomes and Cancer</i> , 2010, 49, 439-451.	1.5	68
4	Complex, Not Monosomal, Karyotype Is the Cytogenetic Marker of Poorest Prognosis in Patients With Primary Myelodysplastic Syndrome. <i>Journal of Clinical Oncology</i> , 2013, 31, 916-922.	0.8	65
5	Distinction between Asymptomatic Monoclonal B-cell Lymphocytosis with Cyclin D1 Overexpression and Mantle Cell Lymphoma: From Molecular Profiling to Flow Cytometry. <i>Clinical Cancer Research</i> , 2014, 20, 1007-1019.	3.2	44
6	Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of <i>TP53/ATM FISH</i> deletions. <i>Oncotarget</i> , 2017, 8, 54297-54303.	0.8	44
7	Better prognosis for patients with del(7q) than for patients with monosomy 7 in myelodysplastic syndrome. <i>Cancer</i> , 2012, 118, 127-133.	2.0	43
8	Chronic lymphocytic leukaemia with 17p deletion: a retrospective analysis of prognostic factors and therapy results. <i>British Journal of Haematology</i> , 2012, 157, 67-74.	1.2	39
9	Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients. <i>Blood Cancer Journal</i> , 2018, 8, 91.	2.8	38
10	Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-. <i>Haematologica</i> , 2008, 93, 1001-1008.	1.7	36
11	Additional trisomies amongst patients with chronic lymphocytic leukemia carrying trisomy 12: the accompanying chromosome makes a difference. <i>Haematologica</i> , 2016, 101, e299-e302.	1.7	35
12	Automated Neutrophil Morphology and Its Utility in the Assessment of Neutrophil Dysplasia. <i>Laboratory Hematology: Official Publication of the International Society for Laboratory Hematology</i> , 2007, 13, 98-102.	1.2	34
13	Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with <i>TP53</i> aberrations. <i>Oncotarget</i> , 2016, 7, 80916-80924.	0.8	29
14	A retrospective analysis of myelodysplastic syndromes with thrombocytosis: reclassification of the cases by WHO proposals. <i>Leukemia Research</i> , 2005, 29, 365-370.	0.4	28
15	A high proportion of cells carrying trisomy 12 is associated with a worse outcome in patients with chronic lymphocytic leukemia. <i>Hematological Oncology</i> , 2016, 34, 84-92.	0.8	26
16	Prognostic value of trisomy 8 as a single anomaly and the influence of additional cytogenetic aberrations in primary myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2012, 159, 311-321.	1.2	25
17	Early ROS-mediated DNA damage and oxidative stress biomarkers in Monoclonal B Lymphocytosis. <i>Cancer Letters</i> , 2012, 317, 144-149.	3.2	24
18	A Low Frequency of Losses in 11q Chromosome Is Associated with Better Outcome and Lower Rate of Genomic Mutations in Patients with Chronic Lymphocytic Leukemia. <i>PLoS ONE</i> , 2015, 10, e0143073.	1.1	24

#	ARTICLE	IF	CITATIONS
19	Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: a population-based study. <i>Lancet Haematology</i> , 2015, 2, e260-e266.	2.2	24
20	Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia. <i>European Journal of Haematology</i> , 2016, 97, 33-38.	1.1	23
21	Oxidative imbalance in low/intermediate-1-risk myelodysplastic syndrome patients: The influence of iron overload. <i>Clinical Biochemistry</i> , 2017, 50, 911-917.	0.8	18
22	Chromosome banding analysis and genomic microarrays are both useful but not equivalent methods for genomic complexity risk stratification in chronic lymphocytic leukemia patients. <i>Haematologica</i> , 2022, 107, 593-603.	1.7	18
23	Optical Genome Mapping: A Promising New Tool to Assess Genomic Complexity in Chronic Lymphocytic Leukemia (CLL). <i>Cancers</i> , 2022, 14, 3376.	1.7	18
24	Complex Variant t(9;22) Chromosome Translocations in Five Cases of Chronic Myeloid Leukemia. <i>Advances in Hematology</i> , 2009, 2009, 1-4.	0.6	16
25	Application of FISH 7q in MDS patients without monosomy 7 or 7q deletion by conventional G-banding cytogenetics: Does a 7/7q detection by FISH have prognostic value?. <i>Leukemia Research</i> , 2013, 37, 416-421.	0.4	16
26	Reciprocal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemias: Review of 5,654 patients with an evaluable karyotype. <i>Genes Chromosomes and Cancer</i> , 2013, 52, 753-763.	1.5	15
27	Interstitial 13q14 deletions detected in the karyotype and translocations with concomitant deletion at 13q14 in chronic lymphocytic leukemia: Different genetic mechanisms but equivalent poorer clinical outcome. <i>Genes Chromosomes and Cancer</i> , 2014, 53, 788-797.	1.5	15
28	Excess mortality in the myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2017, 92, 149-154.	2.0	15
29	The division of chronic myelomonocytic leukemia (CMML)-1 into CMML-0 and CMML-1 according to 2016 World Health Organization (WHO) classification has no impact in outcome in a large series of patients from the Spanish group of MDS. <i>Leukemia Research</i> , 2018, 70, 34-36.	0.4	15
30	Chromosome 11 Abnormalities in Myelodysplastic Syndromes. <i>Cancer Genetics and Cytogenetics</i> , 1999, 114, 58-61.	1.0	13
31	Biallelic losses of 13q do not confer a poorer outcome in chronic lymphocytic leukaemia: analysis of 627 patients with isolated 13q deletion. <i>British Journal of Haematology</i> , 2013, 163, 47-54.	1.2	13
32	Increased Oxidative Damage Associated with Unfavorable Cytogenetic Subgroups in Chronic Lymphocytic Leukemia. <i>BioMed Research International</i> , 2014, 2014, 1-5.	0.9	12
33	Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group. <i>American Journal of Hematology</i> , 2020, 95, 604-611.	2.0	12
34	Correlation of myelodysplastic syndromes with i(17)(q10) and TP53 and SETBP1 mutations. <i>British Journal of Haematology</i> , 2015, 171, 137-141.	1.2	11
35	Prognosis Assessment of Early-Stage Chronic Lymphocytic Leukemia: Are We Ready to Predict Clinical Evolution Without a Crystal Ball?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 548-555.e4.	0.2	10
36	Balanced and unbalanced translocations in a multicentric series of 2843 patients with chronic lymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 37-43.	1.5	10

#	ARTICLE	IF	CITATIONS
37	Vascular Endothelial Growth Factor A (VEGFA) Gene Polymorphisms Have an Impact on Survival in a Subgroup of Indolent Patients with Chronic Lymphocytic Leukemia. PLoS ONE, 2014, 9, e101063.	1.1	9
38	Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukemia. A report from the Spanish MDS Group. Leukemia Research, 2017, 63, 85-89.	0.4	9
39	Clinical, biological, and prognostic implications of SF3B1 co-occurrence mutations in very low/low- and intermediate-risk MDS patients. Annals of Hematology, 2021, 100, 1995-2004.	0.8	9
40	Characterizing patients with multiple chromosomal aberrations detected by FISH in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2018, 59, 633-642.	0.6	8
41	Prognostic impact of chromosomal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemia patients. A study by the spanish group of myelodysplastic syndromes. Genes Chromosomes and Cancer, 2016, 55, 322-327.	1.5	7
42	Chronic lymphocytic leukemia with isochromosome 17q: An aggressive subgroup associated with TP53 mutations and complex karyotypes. Cancer Letters, 2017, 409, 42-48.	3.2	6
43	A BCR-ABL1 cutoff of 1.5% at 3 months, determined by the GeneXpert system, predicts an optimal response in patients with chronic myeloid leukemia. PLoS ONE, 2017, 12, e0173532.	1.1	6
44	New translocations in a case of atypical B-cell chronic lymphocytic leukemia: involvement of ATM, MLL, and TP53 genes. Cancer Genetics and Cytogenetics, 2006, 169, 176-178.	1.0	4
45	Transfusion dependence development and disease evolution in patients with MDS and del(5q) and without transfusion needs at diagnosis. Leukemia Research, 2014, 38, 304-309.	0.4	4
46	A two-step approach for sequencing spliceosome-related genes as a complementary diagnostic assay in MDS patients with ringed sideroblasts. Leukemia Research, 2017, 56, 82-87.	0.4	4
47	Fluorescence in situ hybridization analysis does not increase detection rate for trisomy 8 in chronic myelomonocytic leukemia. Leukemia and Lymphoma, 2015, 56, 242-243.	0.6	1
48	Absence of mutations in the activation loop and juxtamembrane domains of VEGFR-1 and VEGFR-2 gene in chronic myelomonocytic leukemia (CMML). Leukemia Research, 2012, 36, e50-e51.	0.4	0